{"id":"W2792603138","doi":"10.1097/coc.0000000000000429","title":"Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma","year":2018,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"Salivary Gland Tumors Diagnosis and Treatment","field":"Medicine","cited_by":206,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Chugai Pharmaceutical; National Institutes of Health; Astellas Pharma; University of Pennsylvania; Ariad Pharmaceuticals; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Discontinuation; Internal medicine; Response Evaluation Criteria in Solid Tumors; Adverse effect; Gastroenterology; Carcinoma; Surgery; Oncology; Progressive disease; Cancer; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003856957,0.0001976147,0.0004019164,0.000207784,0.0002707377,0.0002031256,0.0001768542,0.0001964915,0.001435322],"category_scores_gemma":[0.0002674338,0.00006664321,0.0003140183,0.00017564,0.00012247,0.000142952,0.0001767092,0.0005573736,0.0004024179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003824995,"about_ca_system_score_gemma":0.0004528416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005549306,"about_ca_topic_score_gemma":0.001873621,"domain_scores_codex":[0.9998994,0.0000303539,0.00001099238,0.0000132762,0.00002587576,0.00002010292],"domain_scores_gemma":[0.9999204,0.00001465547,0.00002333123,0.000004797063,0.00001117879,0.00002556198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.01878449,0.00248936,0.02318546,0.002348941,0.0005680915,0.002269939,0.0002559616,0.001197897,0.09482072,0.0006304288,0.01134179,0.8421069],"study_design_scores_gemma":[0.06737168,0.09511032,0.3973344,0.002107393,0.002070841,0.02580215,0.0004277523,0.007801265,0.05429413,0.0019842,0.3455994,0.00009642926],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8934705,0.09051885,0.001676041,0.002386476,0.0002587577,0.001049006,0.0004052736,0.0001430809,0.01009204],"genre_scores_gemma":[0.9761139,0.01936096,0.001284279,0.0007496314,0.00016699,0.0002860486,0.0003760059,0.000006782146,0.001655401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001435322,"threshold_uncertainty_score":0.004801571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08574078329257076,"score_gpt":0.4604282430723585,"score_spread":0.3746874597797878,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}